ARIAD Announces Appointment of Manfred Weigele, Ph.D. As Chief Scientific Officer.CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 4, 1999--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that, effective immediately, Manfred Weigele, Ph.D., a co-founder of ARIAD ARIAD Allison Research Index of Art and Design , has been appointed chief scientific officer, replacing Michael Gilman, Ph.D. in that position. Dr. Weigele has served as senior vice president, physical and chemical sciences and senior vice president, research - chemistry of ARIAD beginning in 1991. Prior to joining ARIAD, from 1985 to 1991, Dr. Weigele was vice president and group director of chemistry research of Hoffmann-LaRoche Inc., where he managed chemistry research. He joined Hoffmann-LaRoche in 1965 after receiving a Ph.D. degree from the University of Wisconsin. "Dr. Weigele's over 30 years of experience in drug discovery and development, as well as structure-based drug design, will provide ARIAD with the leadership and focus needed for meeting the immediate challenges we face in advancing our products through clinical trials," said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. ARIAD Pharmaceuticals (www.ariad.com) is engaged in the discovery and development of orally administered therapeutics based on signal transduction Signal transduction The transmission of molecular signals from a cell's exterior to its interior. Molecular signals are transmitted between cells by the secretion of hormones and other chemical factors, which are then picked up by different cells. technology. The company is developing small-molecule drugs that block intracellular signaling pathways that play a critical role in major diseases, including osteoporosis and immune-related disorders. ARIAD is also developing ARGENT ar·gent n. 1. Heraldry The metal silver, represented by the color white. 2. Archaic Silver or something resembling it. (TM), a proprietary regulated gene expression technology for orally activated protein therapy and for cellular therapy. ARIAD recently announced the commencement of Phase 1 human clinical trials on its small-molecule drug (AP1903) to treat graft-versus-host disease graft-versus-host disease n. A type of incompatibility reaction of transplanted cells against host tissues that possess an antigen not possessed by the donor. Also called graft-versus-host reaction. using ARGENT in patients undergoing allogeneic allogeneic /al·lo·ge·ne·ic/ (-je-ne´ik) 1. having cell types that are antigenically distinct. 2. in transplantation biology, denoting individuals (or tissues) that are of the same species but antigenically bone marrow transplants bone marrow transplant: see bone marrow. . Some of the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including without limitation risks and uncertainties regarding the success of the Company's operations, as well as risks and uncertainties relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc economic conditions, markets, products, competition, intellectual property, clinical trials, services and prices, key employees, future capital needs, dependence on our collaborators and other factors discussed under the heading "Cautionary Statement Regarding Forward-Looking Statements" in ARIAD's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the fiscal year ended December 31, 1997 filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion